This result demonstrates a role for the HGF/MET pathway in neutrophil recruitment and function and suggests that MET inhibitor co-treatment may improve responses to cancer immunotherapy in MET-independent tumors by directly activating T cell-mediated anti-cancer immunity (Glodde et al., 2017). This evidence concerns the gene HGF and cancer.